Research funding

Ongoing

• since 2024 - INTER-EXCELLENCE project "Unique isoform-selective topoisomerase II inhibitors as a tool for effective and safe anticancer therapy" (reg. no. LUAUS24335) (principal investigator: Jaroslav Roh)

• since 2024 - Members of EU-funded project New Technologies for Translational Research in Pharmaceutical Sciences /NETPHARM (CZ.02.01.01/00/22_008/0004607)

• since 2024 - Members of the EU-funded project Pre-application research of drugs for oncological diseases and for the prevention and treatment of serious complications caused by them - OncoPharm (CZ.02.01.01/00/23_021/0008442)

• since 2024 - Czech Health Research Council project NW24-08-00135 Sensitizing Gram-negative bacteria to antibiotic treatment using efflux pump inhibitors (co-principal investigator: Jaroslav Roh)

• since 2022 - Members of the project National Institute of virology and bacteriology - NIVB (Programme EXCELES, ID Project No. LX22NPO5103) funded by the European Union - Next Generation EU.

Student projects

• Grant agency of Charles University project No. 155124: Design and synthesis of isoform-selective topoisomerase II inhibitors; PI: Eliška Cejnarová, 2024-2026.
• Grant agency of Charles University project No. 238323: Antimycobacterial activity switching in a new class of pyrimidine-based antitubercular agents; PI: Ondřej Kovář, 2023-2025.
• Grant agency of Charles University project No. 361422: Synthesis and study of cardioprotective activity of topoisomerase II beta inhibitors; PI: Marek Macuš, 2022-2024.
• Grant agency of Charles University project No. 392822: Structure-activity relationships in the group of antimycobacterial pyrimidine derivatives; PI: Martin Kufa, 2022-2024.

Past (since 2015)

• 2021-2023: Czech Science Foundation 21-16195S - Chemical biology approach to study anthracycline cardiotoxicity and pharmacological cardioprotection with focus on topoisomerase II beta
• 2019-2023 EU-funded project Pre-application research into innovative medicines and medical technologies (InoMed), reg. no. CZ.02.1.01/0.0/0.0/18_069/0010046
• 2021-2024 Czech Health Research Council project NU21-05-00446 From hit-to-lead candidate – development of novel agents to combat tuberculosis
• 2018-2023 EU-funded project Efficiency and safety improvement of current drugs and nutraceuticals: advanced methods – new challenge (EFSA-CDN). Reg. No. CZ.02.1.01/0.0/0.0/16_019/0000841
• 2020-2022 - Czech Science Foundation (GA ČR): 20-19638Y (Design and investigation of novel antimicrobial agents active against drug-resistant and biofilm-forming gram-positive bacteria; principle investigator Assoc. Prof. M. Krátký)
• 2018-2020: Czech Science Foundation 18-08169S - Study of individual topoisomerase ii isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines
• 2017-2019 - Czech Science Foundation (GA ČR): 17-27514Y (Peptide Drug Delivery Systems Targeting Macrophages for Antimycobacterial Active Compounds; principle investigator Dr. M. Krátký)
• 2014-2016: Czech Science Foundation 14-08423S - Structure-activity-toxicity relationships studies in the group of small-molecule compounds with antimycobacterial activity
• 2013-2017: Czech Science Foundation (GA ČR): 13-15008S - New potential cardioprotective agents: study of structure-activity relationships in various types of myocardial injury
• 2012-2015 - Ministry of Health IGA NT 13346: Design and enzyme targeting of antibacterial active compounds against multidrug resistant strains. (principle investigator Vinšová J.)
• 2012-2017: Charles University in Prague: "Centre for research of toxic and protective effects of drugs on cardiovascular system"